Aeso Holding Limited (8341) AI Stock Analysis

• Market Cap: HK$46.32M
• Dividend Yield: N/A
• Average Volume (3M): 110.89K
• Price to Earnings (P/E): 1.0
• Beta (1Y): -0.31
• Revenue Growth: -26.94%
• EPS Growth: -38.23%
• Country: HK
• Employees: 45
• Sector: Industrials
• Sector Strength: 72
• Industry: Consulting Services
• EPS (TTM): 0.04
• Shares Outstanding: 240,000,000
• 10 Day Avg. Volume: 157,950
• 30 Day Avg. Volume: 110,887
• PEG Ratio: -0.14
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.10
• P/FCF Ratio: -37.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: HK$0.20 ▼(-23.46% Downside)
• Action: Reiterated Date: 01/13/26
• Date: Action: Reiterated 01/13/26

The score is held back primarily by weak financial performance—declining revenue, thin margins, high leverage, and especially negative operating/free cash flow. This is partially offset by strong recent technical momentum (price above key moving averages with a positive MACD) and a low P/E valuation.

Positive Factors

Diversified healthcare business model

Aeso’s multi-pronged business model—product sales across pharmaceuticals, biotech and wellness plus licensing and collaborations—reduces dependency on any single product or market. This structural diversification supports more stable revenue mix and multiple pathways to growth over the medium term.

R&D investment and institutional partnerships

Sustained investment in R&D and partnerships with research institutions create a durable pipeline advantage. These collaborations lower development cost, accelerate time-to-market for new therapies, and strengthen long-term product competitiveness and licensing opportunities.

Improving gross profit margin

A rising gross margin to 17.5% indicates better direct cost control or improved product mix. If maintained, higher gross margins provide structural cushion for the P&L, aiding recovery of operating profitability even if top-line growth is gradual.

Negative Factors

Sharp revenue decline

A pronounced ~30% revenue drop materially weakens scale economics and jeopardizes fixed-cost absorption. Persistent top-line contraction undermines R&D ROI, margin recovery and the company's ability to fund strategic initiatives without external financing.

Negative operating and free cash flow

Continued negative operating and free cash flows indicate the business is burning cash, limiting capacity to invest, pay down debt, or withstand market shocks. Structural cash deficits increase reliance on financing and constrain strategic flexibility over several quarters.

Elevated financial leverage

A debt-to-equity ratio of 1.28 signals elevated leverage that reduces balance sheet resilience. With weak cash flow and falling revenue, high debt raises refinancing and interest coverage risk, limiting the company’s ability to fund R&D or pursue opportunistic investments.

Aeso Holding Limited Business Overview & Revenue Model

Company Description

Aeso Holding Limited, an investment holding company, provides fitting-out and renovation contracting services in Hong Kong. It undertakes fitting-out works for the construction of newly built commercial premises and residential developments; and renovation works, including alteration and addition works for existing commercial premises. The company also offers interior design services. It serves property developers, contractors, landlords, government authority, and international and local retail brands. Aeso Holding Limited was incorporated in 2008 and is headquartered in Sheung Wan, Hong Kong.

How the Company Makes Money

Aeso Holding Limited generates revenue through multiple key streams, primarily from the sale of healthcare products, including pharmaceuticals and wellness solutions. The company also earns income from licensing agreements and collaborations with other healthcare firms, which allow it to expand its product offerings and market reach. Additionally, Aeso may benefit from strategic partnerships with research institutions and healthcare providers, enhancing its capabilities in product development and market entry. The company's revenue model is further supported by its investment in research and development, which leads to the introduction of innovative products that meet evolving consumer needs in the healthcare sector.

Aeso Holding Limited Financial Statement Overview

Summary

Weak fundamentals: income statement shows a sharp revenue decline (-30.4%) and low operating margins, the balance sheet indicates elevated leverage (debt-to-equity 1.28) with lower ROE (11.4%), and cash flow is the biggest concern with negative operating and free cash flows.

Income Statement

Aeso Holding Limited has shown a declining revenue trend with a significant drop of 30.4% in the latest year. Gross profit margin improved slightly to 17.5%, but net profit margin decreased to 2.8%. The EBIT and EBITDA margins are relatively low, indicating challenges in operational efficiency.

Balance Sheet

The company has a high debt-to-equity ratio of 1.28, indicating significant leverage, which could pose financial risk. Return on equity has decreased to 11.4%, reflecting reduced profitability. The equity ratio is not provided, but the overall leverage suggests a cautious approach to financial stability.

Cash Flow

Aeso Holding Limited's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is significantly negative, and the operating cash flow to net income ratio is negative, indicating cash flow challenges.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	210.22M	239.69M	262.62M	218.01M	125.05M
Gross Profit	36.76M	37.50M	35.95M	29.91M	15.83M
EBITDA	12.85M	13.53M	12.54M	11.20M	-707.00K
Net Income	5.91M	8.11M	8.26M	8.16M	-5.65M
Balance Sheet
Total Assets	161.18M	172.95M	120.03M	115.61M	88.29M
Cash, Cash Equivalents and Short-Term Investments	35.67M	37.01M	16.91M	18.99M	19.75M
Total Debt	65.98M	58.25M	39.98M	35.13M	9.96M
Total Liabilities	109.44M	127.11M	82.30M	87.50M	68.86M
Stockholders Equity	51.74M	45.84M	37.73M	28.11M	19.43M
Cash Flow
Free Cash Flow	-563.00K	-287.00K	870.00K	-19.30M	-24.39M
Operating Cash Flow	-358.00K	-278.00K	1.36M	-19.13M	-24.32M
Investing Cash Flow	-197.00K	-11.61M	-5.47M	735.00K	-71.00K
Financing Cash Flow	-1.38M	15.31M	2.60M	18.31M	-2.54M

Aeso Holding Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8341, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.20, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.74 is Neutral, neither overbought nor oversold. The STOCH value of 52.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8341.

Aeso Holding Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
8341	55 Neutral	HK$46.32M	0.97	10.44%	―	-26.94%	-38.23%
8501	50 Neutral	HK$114.81M	-3.32	-5.93%	―	50.50%	27.48%
8455	47 Neutral	HK$112.32M	-4.63	-601.82%	―	4.00%	13.57%
8040	46 Neutral	HK$136.00M	-3.32	-57.83%	―	-3.47%	-57.53%
3893	46 Neutral	HK$420.42M	-0.40	―	―	-24.93%	-72.69%
8173	41 Neutral	HK$25.41M	-2.54	-19.25%	―	46.11%	54.20%